Skip to main content
AMGN
NASDAQ Life Sciences

Amgen 10-Q: Q3 Revenue $10.4B, Diluted EPS $7.08; TAVNEOS and IRS Disputes Detailed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$464.92
Mkt Cap
$249.372B
52W Low
$292.12
52W High
$475.645
52W Position info
59% above low
Off High info
2.3% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AMGN sits 59% above its 52-week low of $292.12.

Summary

Amgen's Q3 10-Q shows revenue of $10,365 million and diluted EPS of $7.08, with biosimilar erosion in Prolia and XGEVA offset by Repatha and newer products. It also details the pending FDA withdrawal proposal for TAVNEOS and an expanding IRS dispute now covering 2016-2018 penalties.


Key Events · Earnings and Guidance · AMGN

  • Q3 Revenue $10.4B, EPS $7.08

    Total revenues were $10,365 million versus $9,557 million a year earlier, and diluted EPS was $7.08 versus $5.93. Nine-month revenues reached $29,037 million with diluted EPS of $14.79.

  • Biosimilars Erode Prolia and XGEVA

    Prolia sales fell 45% to $632 million and XGEVA fell 47% to $288 million in Q3 as multiple biosimilars launched in the U.S. and rest of world. Repatha grew 37% to $1,085 million and UPLIZNA and IMDELLTRA more than doubled.

  • TAVNEOS $2.2B Asset Under FDA Threat

    The U.S. TAVNEOS intangible carries a $2.2 billion book value while an FDA proposal to withdraw approval is pending; CDER has not responded to Amgen's July 23, 2026 submission supporting a hearing.

  • IRS Dispute Expands to 2016-2018

    Amgen received a September 2026 draft IRS notice asserting penalties for 2016-2018 similar to the $2.0 billion asserted for 2013-2015. Proposed adjustments for 2010-2015 total roughly $3.6 billion and $5.1 billion plus interest, with a Tax Court decision expected no earlier than late 2026 or early 2027.


Analysis · AMGN · Life Sciences

The 10-Q fills in the full GAAP picture behind Tuesday's 8-K: Q3 revenue of $10,365 million and net income of $3,864 million, with nine-month operating cash flow of $10,432 million funding $4,083 million of dividends and $3,883 million of debt repayment. Growth is not uniform — Repatha rose 37% to $1,085 million while Prolia fell 45% to $632 million and XGEVA fell 47% to $288 million as biosimilars took hold, so the franchise is rotating rather than simply expanding. Two unresolved items carry real money: the $2.2 billion TAVNEOS U.S. intangible sits behind an FDA proposal to withdraw approval, and the IRS has now sent a draft penalty notice for 2016-2018 on top of the $3.6 billion and $5.1 billion proposed adjustments for 2010-2015, with a Tax Court decision not expected before late 2026 or early 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMGN was trading at $464.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.4B. The 52-week trading range was $292.12 to $475.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $444.00 info
Change: -$33.40 (-7%) info
Market Cap: $240.105B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $444.00 info
Change: -$19.00 (-4%) info
Market Cap: $240.105B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $444.00 info
Change: -$16.57 (-4%) info
Market Cap: $240.105B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $444.00 info
Change: -$4.79 (-1%) info
Market Cap: $240.105B info
AMGN
Oct 24, 2026, 10:30 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $439.26
Real-time Price: $444.00 info
Change: +$4.74 (+1%) info
Market Cap: $240.105B info